NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has provided new details on its Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus (BDBV) outbreak and other Ebola viruses in the Democratic Republic of Congo. The trial is proceeding as designed, with enrollment in Phase IIA beginning on or about September 23, 2026. Phase IIA aims to identify an optimal, well-tolerated dosing regimen and serve as a go/no-go step before Phase IIB, a randomized controlled trial designed to evaluate efficacy.
NV-387 is designed to attack the virus and reduce viral load, and is delivered as an oral gummy that dissolves in the mouth without requiring water or swallowing effort. If successful, the oral treatment could be readily deployed in resource-limited settings. NanoViricides characterized NV-387 as a broad-spectrum antiviral that mimics a host-side feature used by Ebola viruses, providing a rationale for potential activity against Bundibugyo and other Ebola viruses.
This development is significant because Ebola outbreaks, particularly those caused by the Bundibugyo strain, often occur in remote areas with limited healthcare infrastructure. An oral treatment that is easy to administer could improve access and outcomes, potentially reducing the spread of the virus. The trial's progression also highlights the potential of NanoViricides' nanoviricide platform, which is based on technology licensed from TheraCour Pharma, Inc. The company's lead drug candidate, NV-387, is also being developed for other viral infections, including RSV, COVID, Influenza, and MPOX/Smallpox.
For investors, the update signals progress in NanoViricides' pipeline. The company's newsroom, available at https://ibn.fm/NNVC, provides ongoing updates. More information about the company can be found at www.nanoviricides.com. The full press release is accessible at https://ibn.fm/zjg8X.
BioMedWire, a specialized communications platform for the biotech sector, distributed the announcement. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers services such as InvestorWire for wire distribution and editorial syndication to 5,000+ outlets. Additional services include press release enhancement and social media distribution. For more details, visit BioMedWire and review the disclaimer at https://www.BioMedWire.com/Disclaimer.
